Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05400499 · ClinicalTrials.gov registry record

Deep Brain Stimulation for Visuomotor Function in Parkinson's Disease

A clinical trial of Parkinson's Disease, sponsored by VA Office of Research and Development.

Recruiting
Registry status
40
Enrollment target
1
Study location

NCT05400499: Recruiting study of Parkinson's Disease, sponsored by VA Office of Research and Development.

NCT05400499 is a study of Parkinson's Disease that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 40 participants, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05400499, a study of Parkinson's Disease, is actively recruiting participants, sponsored by VA Office of Research and Development.

RECRUITING
Registry status
40 participants
Enrollment target
1
Study location

Study Summary

Inability to align and refocus the eyes on the objects at different depths, i.e., vergence impairment, frequently affects the quality of life in patients with Parkinson's disease. Our study aims to understand the location-specific effects of subthalamic region deep brain stimulation on vergence by integrating the patient-specific deep brain stimulation models and high-resolution eye-tracking measures. The knowledge gained will allow us to find the most beneficial stimulation location and parameters for improving binocular coordination and vergence while preserving the ability to treat motor symptoms in Parkinson's disease.

Primary Outcome

The investigators will measure dynamic eye alignment (vergence, the difference between the horizontal angular positions of the right and left eye) with non-invasive high-resolution video oculography. Derives parameters such as ratio of actual versus desired vergence, delay of vergence onset after target shift, peak vergence velocity, and congruency between the two eyes will be incorporated in an equation. The equation output will be used as a measure of the effects of subthalamic region deep bra

Conditions Studied

Parkinson's Disease

Study Locations (1)

Ohio

  • Louis Stokes VA Medical Center, Cleveland, OH - Cleveland

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2022-10-04
Est. Completion 2026-07-01
VA Office of Research and Development

1,668 total trials

What NCT05400499 shows while recruiting

NCT05400499 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (94% lower).

The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 0 interventions.

NCT05400499 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT05400499 about?

NCT05400499 is a clinical study titled "Deep Brain Stimulation for Visuomotor Function in Parkinson's Disease". Inability to align and refocus the eyes on the objects at different depths, i.e., vergence impairment, frequently affects the quality of life in patients with Parkinson's disease. Our study aims to understand the location-specific effects of subthalamic region deep brain stimulation on vergence by i...

What is the current status of trial NCT05400499?

This trial is currently recruiting. The enrollment target is 40 participants. The study started on 2022-10-04. Estimated completion is 2026-07-01.

What conditions does trial NCT05400499 study?

This clinical trial studies the following conditions: Parkinson's Disease.

Who is sponsoring clinical trial NCT05400499?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05400499 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05400499's enrollment target sits among peer trials

40 92nd of 158 higher than 63 of 158 other Parkinson's Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05400499

Source: ClinicalTrials.gov NCT05400499, the US trial registry maintained by the National Library of Medicine. NCT05400499 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.